

INCARA PHARMACEUTICALS CORP
Form SC 13G/A
February 14, 2001

SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549

SCHEDULE 13G
(Rule 13d-102)

INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT
TO RULES 13d-1(b)(c), AND (d) AND AMENDMENTS THERETO FILED
PURSUANT TO RULE 13d-2(b)
(AMENDMENT NO. 5)/1/

Incara Pharmaceuticals Corporation

(Name of Issuer)

Common Stock, \$.001 par value

(Title of Class of Securities)

458 44M 106

(CUSIP Number)

December 31, 2000

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-(c)

Rule 13d-1(d)

/1/ The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 CUSIP NO. 458 44M 106

1 NAMES OF REPORTING PERSONS
 I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY).
 Interneuron Pharmaceuticals, Inc. 04-3047911

2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
 (a)
 (b)
 Not Applicable

3 SEC USE ONLY

4 CITIZENSHIP OR PLACE OF ORGANIZATION
 Delaware

		SOLE VOTING POWER
NUMBER OF	5	
SHARES		482,011

BENEFICIALLY	6	SHARED VOTING POWER
OWNED BY		0

EACH	7	SOLE DISPOSITIVE POWER
REPORTING		482,011

PERSON	8	SHARED DISPOSITIVE POWER
WITH		0

9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
 482,011

10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
 (SEE INSTRUCTIONS)

11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
 Approximately 5.8% (Based on the number of shares of outstanding Common
 Stock of Incara Pharmaceuticals Corporation (the "Issuer") as set forth in
 the Issuer's Proxy Statement filed on February 9, 2001.)

TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

Edgar Filing: INCARA PHARMACEUTICALS CORP - Form SC 13G/A

12

CO

Page 3 of 5

Item 1(a). Name of Issuer:

Incara Pharmaceuticals Corporation

Item 1(b). Address of Issuer's Principal Executive Offices:

P.O. Box 14287, 3200 East Highway 54
Cape Fear Building, Suite 300
Research Triangle Park, NC 27709

Item 2(a). Name of Person Filing:

Interneuron Pharmaceuticals, Inc. ("IPI")

Item 2(b). Address of Principal Business Office or, if None, Residence:

One Ledgemont Centre, 99 Hayden Avenue, Lexington, MA 02421

Item 2(c). Citizenship:

IPI is a Corporation organized under the laws of the State of Delaware

Item 2(d). Title of Class of Securities:

Common Stock, \$.001 par value ("Shares")

Item 2(e). CUSIP Number:

458 44M 106

Item 3. If This Statement is Filed Pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a:

- (a) Broker or dealer registered under Section 15 of the Exchange Act.
- (b) Bank as defined in Section 3(a)(6) of the Exchange Act.
- (c) Insurance company as defined in Section 3(a)(19) of the Exchange Act.
- (d) Investment company registered under Section 8 of the Investment Company Act.
- (e) An investment advisor in accordance with Rule 13d-1(b)(1)(ii)(E);
- (f) An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F);
- (g) A parent holding company or control person in accordance with Rule 13d-(b)(1)(ii)G;
- (h) A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act;

Edgar Filing: INCARA PHARMACEUTICALS CORP - Form SC 13G/A

- (i) A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act;
- (j) Group, in accordance with Rule 13d-1(b)(1)(ii)(J).

Page 4 of 5

If this statement is filed pursuant to rule 13d-1(c), check this box.

Item 4. Ownership.

Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

(a) Amount beneficially owned:

IPI is the beneficial owner of 482,011 Shares

(b) Percent of class:

The 482,011 Shares beneficially owned by IPI constitute approximately 5.8% of the Issuer's outstanding Common Stock

(c) (i)-(iv):

Reference is made to Items 5-8 of the cover page

Instruction. For computations regarding securities which represent a right to acquire an underlying security see Rule 13d-(d)(1).

Item 5. Ownership of Five Percent or Less of a Class.

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following .

Instruction. Dissolution of a group requires a response to this item.

Item 6. Ownership of More than Five Percent on Behalf of Another Person.

Not Applicable

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Report on by the Parent Holding Company.

Not Applicable

Item 8. Identification and Classification of Members of the Group.

Not Applicable

Item 9. Notice of Dissolution of Group.

Not Applicable

Edgar Filing: INCARA PHARMACEUTICALS CORP - Form SC 13G/A

Item 10. Certifications.

Not Applicable

Page 5 of 5

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

February 14, 2001

(Date)

INTERNEURON PHARMACEUTICALS, INC.

By: /s/ Glenn L. Cooper, M.D.

(Name/Title)

The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative. If the statement is signed on behalf of a person by his authorized representative (other than an executive officer or general partner of the filing person) , evidence of the representative's authority to sign on behalf of such person shall be filed with the statement, provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference. The name and any title of each person who signs the statement shall be typed or printed beneath his signature.

Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7(b) for other parties for whom copies are to be sent.

Attention: Intentional misstatements or omissions of fact constitute federal criminal violations (see 18 U.S.C. 1001).